Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy

Abstract Background Three vascular endothelial growth factor (VEGF) inhibitors, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second‐line chemotherapy. The difference in outcome between the three dru...

Full description

Bibliographic Details
Main Authors: Hiroki Osumi, Eiji Shinozaki, Akira Ooki, Takeru Wakatsuki, Daisaku Kamiimabeppu, Taro Sato, Izuma Nakayama, Mariko Ogura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.3638